Cancer cells employ a number of mechanisms to escape immunosurveillance and facilitate
tumour progression. The recent explosion of interest in immunotherapy, especially immune …

Peripheral T-cell lymphoma (PTCL) is a set of rare and highly heterogeneous group of
mature T-and NK-cell neoplasms associated with poor outcomes and lack of standard and …

Background Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone
deacetylase inhibitor. In an exploratory study, the combination of tucidinostat with …

Background Chidamide is a novel benzamide type of subtype-selective histone deacetylase
(HDAC) inhibitor with unique mechanisms of action compared with marketed HDAC …

Immune checkpoint blockades, such as inhibitors against programmed death 1 (PD-1) and
its ligand (PD-L1), have received extensive attention in the past decade because of their …

PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis
antigen (CTA) with restricted expression in somatic tissues and re-expression in various …

Patients with hematologic malignancies relapsing after allogeneic blood or marrow
transplantation (BMT) have limited response to conventional salvage therapies, with an …

Although the earliest—rudimentary—attempts at exploiting the immune system for cancer
therapy can be traced back to the late 18th Century, it was not until the past decade that …

Bone marrow transplantation is regarded as the most effective immunotherapy for
hematologic cancer, but it generally faces difficulties in matching. Aberrant expression of …

PRAME is a cancer-testis antigen (CTA) and potential immuno-therapeutic target, but has
not been well-studied in epithelial ovarian cancer (EOC) or its high grade serous (HGSC) …